187 related articles for article (PubMed ID: 1354432)
1. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
Saathoff N; Lode H; Neider K; Depperman KM; Borner K; Koeppe P
Antimicrob Agents Chemother; 1992 Apr; 36(4):796-800. PubMed ID: 1354432
[TBL] [Abstract][Full Text] [Related]
2. Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil.
Blouin RA; Kneer J; Ambros RJ; Stoeckel K
Antimicrob Agents Chemother; 1990 Sep; 34(9):1744-8. PubMed ID: 1981000
[TBL] [Abstract][Full Text] [Related]
3. In vitro Spectroscopic studies on drug interaction of cefpodoxime proxetil and H2 receptor blockers.
Iqbal S; Hassan S; Hassan A; Ali M; Nazim U; Zaheer E; Ahmed A; Hussain K; Shereen -; Furqan H
Pak J Pharm Sci; 2019 Mar; 32(2 (Supplementary)):881-887. PubMed ID: 31103987
[TBL] [Abstract][Full Text] [Related]
4. A review of the pharmacokinetics of cefpodoxime proxetil.
Borin MT
Drugs; 1991; 42 Suppl 3():13-21. PubMed ID: 1726203
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
Borin MT; Hughes GS; Patel RK; Royer ME; Cathcart KS
J Clin Pharmacol; 1991 Dec; 31(12):1137-45. PubMed ID: 1761737
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.
Tremblay D; Dupront A; Ho C; Coussediere D; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():21-8. PubMed ID: 2292526
[TBL] [Abstract][Full Text] [Related]
7. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.
Hughes GS; Heald DL; Barker KB; Patel RK; Spillers CR; Watts KC; Batts DH; Euler AR
Clin Pharmacol Ther; 1989 Dec; 46(6):674-85. PubMed ID: 2557183
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine.
Kees F; Wellenhofer M; Bröhl K; Grobecker H
Arzneimittelforschung; 1996 Apr; 46(4):435-8. PubMed ID: 8740095
[TBL] [Abstract][Full Text] [Related]
9. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H; Böttcher MF; Ochmann K
Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on absorption of cefpodoxime proxetil oral suspension in adults.
Borin MT; Forbes KK
Antimicrob Agents Chemother; 1995 Jan; 39(1):273-5. PubMed ID: 7695323
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.
Gehanno P; Andrews JM; Ichou F; Sultan E; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():47-51. PubMed ID: 2292530
[TBL] [Abstract][Full Text] [Related]
13. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
Brown SA; Boucher JF; Hubbard VL; Prough MJ; Flook TF
J Vet Pharmacol Ther; 2007 Aug; 30(4):320-6. PubMed ID: 17610405
[TBL] [Abstract][Full Text] [Related]
14. The bioavailability of cefpodoxime proxetil tablets relative to an oral solution.
Borin MT; Forbes KK; Hughes GS
Biopharm Drug Dispos; 1995 May; 16(4):295-302. PubMed ID: 7548778
[TBL] [Abstract][Full Text] [Related]
15. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Frampton JE; Brogden RN; Langtry HD; Buckley MM
Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
[TBL] [Abstract][Full Text] [Related]
16. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
Fulton B; Perry CM
Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.
Johnson CA; Ateshkadi A; Zimmerman SW; Hughes GS; Craig WA; Carey PM; Borin MT
Antimicrob Agents Chemother; 1993 Dec; 37(12):2650-5. PubMed ID: 8109931
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.
Dumont R; Guetat F; Andrews JM; Sultan E; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():41-6. PubMed ID: 2292529
[TBL] [Abstract][Full Text] [Related]
19. Effects of food intake and age on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. Comparison with cefpodoxime proxetil.
Totsuka K; Shimizu K; Mori N; Sugihara T; Sakai A; Yamaji S; Michisuji Y; Shinohara Y; Kubo A; Tokuoka H
Int J Antimicrob Agents; 2001 Nov; 18(5):463-9. PubMed ID: 11711262
[TBL] [Abstract][Full Text] [Related]
20. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
